









Markets
/
Stocks
/
nasdaq-kymr
/

Kymera Therapeutics Inc

KYMR

61.260USD

+2.600+4.43%

Close 11/10, 16:00（ET）Quotes delayed by 15 min

4.39BMarket Cap

LossP/E TTM



Kymera Therapeutics Inc

61.260

+2.600+4.43%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Kymera Therapeutics Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kymera Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

8 / 407

Overall Ranking

53 / 4611

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 23 analysts

Buy

Current Rating

76.182

Target Price

+29.87%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Kymera Therapeutics Inc Highlights

StrengthsRisks

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.

Growing

The company is in a growing phase, with the latest annual income totaling USD 47.07M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 47.07M.

Undervalued

The company’s latest PE is -16.97, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 80.49M shares, increasing 1.93% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 29.93K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 8.47, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 2.76M, representing a year-over-year decrease of 26.12%, while its net profit experienced a year-over-year decrease of 31.51%.

Score

Industry at a Glance

Previous score

8.47

Change



Financials

8.63

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.61

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.43

Key Metrics

Free cash flow

No Data

Kymera Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 6.84, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -16.97, which is -77.43% below the recent high of -3.83 and -30.99% above the recent low of -22.23.

Score

Industry at a Glance

Previous score

6.84

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 8/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 8.87, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Kymera Therapeutics Inc is 72.50, with a high of 98.00 and a low of 65.00.

Score

Industry at a Glance

Previous score

8.87

Change

Support & Resistance

No Data

Analyst Rating

Based on 23 analysts

Buy

Current Rating

76.182

Target Price

+29.87%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Kymera Therapeutics Inc

KYMR

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 8.85, which is higher than the Biotechnology & Medical Research industry's average of 6.59. Sideways: Currently, the stock price is trading between the resistance level at 65.06 and the support level at 56.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.08

Change

1.77

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.739

Neutral

RSI(14)

57.241

Neutral

STOCH(KDJ)(9,3,3)

62.208

Neutral

ATR(14)

3.279

Low Volatility

CCI(14)

60.423

Neutral

Williams %R

25.926

Buy

TRIX(12,20)

0.362

Sell

StochRSI(14)

88.121

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

60.144

Buy

MA10

60.570

Buy

MA20

59.947

Buy

MA50

54.588

Buy

MA100

49.181

Buy

MA200

41.503

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-10

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 111.88%, representing a quarter-over-quarter increase of 3.06%. The largest institutional shareholder is PRFDX, holding a total of 6.80M shares, representing 9.45% of shares outstanding, with 10.19% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

T. Rowe Price Associates, Inc.

Star Investors

6.80M

+2.32%

Baker Bros. Advisors LP

6.65M

+10.93%

Avoro Capital Advisors LLC

6.56M

+1.48%

BVF Partners L.P.

5.50M

+6.60%

Fidelity Management & Research Company LLC

5.43M

+23.20%

The Vanguard Group, Inc.

Star Investors

5.61M

+7.41%

Wellington Management Company, LLP

5.37M

-10.42%

Atlas Venture

4.90M

BlackRock Institutional Trust Company, N.A.

3.52M

-3.02%

Invus Public Equities Advisors, LLC

3.43M

+5.80%

Risk Assessment

Currency: USD Updated: 2025-11-10

The company’s current risk assessment score is 6.26, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 2.30. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.